Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients

Completed · Phase 2 · Has a placebo group

Conditions studied: Diabetic Nephropathy

In brief

The purpose of this study is to determine whether VPI-2690B Injection is effective in the treatment of diabetic nephropathy.

Key facts

Study ID

NCT02251067

Run by

Vascular Pharmaceuticals, Inc.

People needed

165

Starts

2014-09-01

Expected to finish

2017-03-01

Last updated by the study team

2017-03-28

Who can join

Age: 21 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• documented diabetic nephropathy in patients with either Type 1 or Type 2 diabetics
• HbA1c of 7.5-10.5%
• eGFR 30-110 mL/min/1.73m2
• stable ACEi/ARB dose regimen
• stable blood pressure
• BMI less than or equal to 45 kg/m2

You may not qualify if…

• non-diabetic renal disease
• history of solid organ or islet cell transplant
• history of malignancy within previous 5 years
• systemic immunosuppression therapy
• clinically significant liver disease, hepatitis B or C or HIV
• monoclonal antibody treatment within previous year
• recent acute renal injury or major surgery
• significant, recent body weight change
• biopsy proven glomerular disease

Where it is running

• Study site — Birmingham, Alabama, United States
• Study site — Little Rock, Arkansas, United States
• Study site — La Mesa, California, United States
• Study site — Riverside, California, United States
• Study site — Sacramento, California, United States
• Study site — Tustin, California, United States
• Study site — Cooper City, Florida, United States
• Study site — Coral Springs, Florida, United States
• Study site — Hialeah, Florida, United States
• Study site — Miami, Florida, United States
• Study site — St. Petersburg, Florida, United States
• Study site — Winter Park, Florida, United States
• Study site — Columbus, Georgia, United States
• Study site — Idaho Falls, Idaho, United States
• Study site — Mount Prospect, Illinois, United States
• Study site — Peoria, Illinois, United States
• Study site — Merrillville, Indiana, United States
• Study site — Boston, Massachusetts, United States
• Study site — Flint, Michigan, United States
• Study site — Kansas City, Missouri, United States
• Study site — Las Vegas, Nevada, United States
• Study site — Albany, New York, United States
• Study site — Asheville, North Carolina, United States
• Study site — Greenville, North Carolina, United States
• Study site — Morehead City, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.